Propanc Biopharma accelerates Phase 1b first-in-human PRP trial in advanced solid tumors

PUBT · 3d ago
Propanc Biopharma accelerates Phase 1b first-in-human PRP trial in advanced solid tumors
  • Propanc Biopharma on Aug. 6, 2026 flagged new preclinical, early translational PRP data in pancreatic cancer models, not yet presented at a scientific meeting.
  • Studies showed strong tumor control, fewer metastases, longer survival, favorable tolerability signals, supporting a differentiated mechanism aimed at resistance.
  • Timeline accelerated for a Phase 1b first-in-human trial in advanced solid tumors, with pancreatic cancer a priority; an Australian trial application is planned soon.
  • PRP, an intravenous pancreatic proenzyme combination, already holds FDA Orphan Drug Designation for pancreatic cancer.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Propanc Biopharma Inc. published the original content used to generate this news brief on August 06, 2026, and is solely responsible for the information contained therein.